FR21C1029I2 - Hormones de croissance avec efficacité in vivo prolongée - Google Patents
Hormones de croissance avec efficacité in vivo prolongéeInfo
- Publication number
- FR21C1029I2 FR21C1029I2 FR21C1029C FR21C1029C FR21C1029I2 FR 21C1029 I2 FR21C1029 I2 FR 21C1029I2 FR 21C1029 C FR21C1029 C FR 21C1029C FR 21C1029 C FR21C1029 C FR 21C1029C FR 21C1029 I2 FR21C1029 I2 FR 21C1029I2
- Authority
- FR
- France
- Prior art keywords
- prolonged
- growth hormones
- vivo effectiveness
- vivo
- effectiveness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000122 growth hormone Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29730510P | 2010-01-22 | 2010-01-22 | |
EP10151405 | 2010-01-22 | ||
EP11705470.0A EP2525834B1 (fr) | 2010-01-22 | 2011-01-24 | Hormones de croissance avec efficacité in vivo prolongée |
PCT/EP2011/050923 WO2011089255A1 (fr) | 2010-01-22 | 2011-01-24 | Hormones de croissance présentant une efficacité in vivo prolongée |
Publications (2)
Publication Number | Publication Date |
---|---|
FR21C1029I1 FR21C1029I1 (fr) | 2021-08-27 |
FR21C1029I2 true FR21C1029I2 (fr) | 2023-06-16 |
Family
ID=42075933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR21C1029C Active FR21C1029I2 (fr) | 2010-01-22 | 2021-07-08 | Hormones de croissance avec efficacité in vivo prolongée |
Country Status (20)
Country | Link |
---|---|
US (5) | US9695226B2 (fr) |
EP (1) | EP2525834B1 (fr) |
JP (2) | JP5875527B2 (fr) |
KR (1) | KR101813595B1 (fr) |
CN (3) | CN106139158B (fr) |
AU (1) | AU2011208625C1 (fr) |
BR (1) | BR112012018116B1 (fr) |
CA (1) | CA2787890C (fr) |
FI (1) | FIC20210013I1 (fr) |
FR (1) | FR21C1029I2 (fr) |
HU (1) | HUS2100029I1 (fr) |
IL (1) | IL220605A (fr) |
MX (1) | MX345736B (fr) |
NO (1) | NO2021023I1 (fr) |
PL (1) | PL2525834T3 (fr) |
RS (1) | RS59459B1 (fr) |
RU (1) | RU2605627C2 (fr) |
SI (1) | SI2525834T1 (fr) |
TW (1) | TWI508737B (fr) |
WO (1) | WO2011089255A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841249B2 (en) * | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
US9211342B2 (en) | 2010-01-22 | 2015-12-15 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds resistant to proteolytic degradation |
TWI508737B (zh) | 2010-01-22 | 2015-11-21 | 諾佛 儂迪克股份有限公司 | 具有延長的活體內功效的生長激素 |
US9289507B2 (en) | 2012-05-17 | 2016-03-22 | Extend Biosciences, Inc. | Carriers for improved drug delivery |
EP2908845A1 (fr) * | 2012-10-17 | 2015-08-26 | Novo Nordisk Health Care AG | Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance |
WO2014166836A1 (fr) | 2013-04-05 | 2014-10-16 | Novo Nordisk A/S | Formulation de composés d'hormone de croissance |
WO2015036553A1 (fr) | 2013-09-16 | 2015-03-19 | Novo Nordisk Health Care Ag | Polymères thiol fonctionnalisés |
JP6603662B2 (ja) * | 2013-12-13 | 2019-11-06 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | タンパク質のチオエーテルコンジュゲーション方法 |
EP3220961B1 (fr) | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Conjugués de vitamine d thérapeutiques |
WO2016065052A1 (fr) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Conjugués insuline vitamine d |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
AU2016209968B2 (en) * | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
PT3348635T (pt) | 2015-09-08 | 2021-03-15 | Japan Chem Res | Novo mutante de albumina do soro humano |
US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
CA2998528A1 (fr) | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Cytotoxines modifiees et leur utilisation therapeutiques |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
WO2017159540A1 (fr) | 2016-03-14 | 2017-09-21 | Jcrファーマ株式会社 | Protéine de fusion albumine sérique-hormone de croissance 20k |
KR20220083784A (ko) | 2019-10-17 | 2022-06-20 | 제이씨알 파마 가부시키가이샤 | 혈청 알부민과 성장 호르몬의 융합 단백질의 제조 방법 |
WO2021085518A1 (fr) | 2019-10-30 | 2021-05-06 | Jcrファーマ株式会社 | Composition pharmaceutique aqueuse contenant une protéine de fusion d'albumine sérique et d'hormone de croissance |
CN115845079B (zh) * | 2022-11-24 | 2023-07-18 | 武汉禾元生物科技股份有限公司 | 一种重组人血清白蛋白与重组人生长激素的偶联物及其制备方法 |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8504099D0 (en) | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8610551D0 (en) | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
DE68929273T2 (de) | 1988-08-24 | 2001-07-05 | American Cyanamid Co | Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung |
US5079230A (en) | 1988-09-12 | 1992-01-07 | Pitman-Moore, Inc. | Stable bioactive somatotropins |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
CA2345497A1 (fr) | 1988-10-28 | 1990-04-28 | Genentech, Inc. | Variantes de l'hormones de croissance et procede de fabrication des variantes de l'hormone de croissance |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
JPH04504246A (ja) | 1989-03-20 | 1992-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | インシュリン刺激ホルモン |
US5101018A (en) | 1989-06-12 | 1992-03-31 | International Minerals & Chemical Corp. | Method for recovering recombinant proteins |
DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
ES2113354T3 (es) * | 1990-05-04 | 1998-05-01 | American Cyanamid Co | Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina. |
US5951972A (en) | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
DK220890D0 (da) | 1990-09-14 | 1990-09-14 | Ole Buchardt | Fremgangsmaade til fremstilling af c-terminalt amiderede peptider |
CA2405246A1 (fr) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees |
JP3267293B2 (ja) | 1990-12-03 | 2002-03-18 | ジェネンテク,インコーポレイテッド | 改変された結合性を有する変異タンパク質の豊富化法 |
IT1251895B (it) | 1991-09-27 | 1995-05-26 | Eniricerche Spa | Mutanti dell'ormone della crescita umano e loro impiego |
EP0555649B1 (fr) | 1992-01-14 | 2004-12-08 | Ajinomoto Co., Inc. | Gène codant pour une transglutaminase de poisson |
DK0652766T4 (da) | 1992-07-31 | 2008-06-09 | Genentech Inc | Vandigt præparat indeholdende humant væksthormon |
ZA936811B (en) | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
EP0693556B1 (fr) | 1994-01-28 | 2004-10-06 | Ajinomoto Co., Inc. | Transglutaminase produite par l'huitre du japon |
DE69535037T2 (de) | 1994-08-26 | 2006-12-07 | Novozymes A/S | Mikrobielle transglutaminasen, ihre herstellung und ihre verwendung |
US6010871A (en) | 1994-09-29 | 2000-01-04 | Ajinomoto Co., Inc. | Modification of peptide and protein |
DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
WO1996022366A1 (fr) | 1995-01-19 | 1996-07-25 | Novo Nordisk A/S | Transglutaminases d'oomycetes |
JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
AU718439B2 (en) | 1995-09-21 | 2000-04-13 | Genentech Inc. | Human growth hormone variants |
US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
PL192359B1 (pl) | 1996-08-30 | 2006-10-31 | Novo Nordisk As | Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37) |
EP0929576A1 (fr) | 1996-08-30 | 1999-07-21 | Novo Nordisk A/S | Derives de glp-2 |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6620916B1 (en) | 1996-09-26 | 2003-09-16 | Ajinomoto Co., Inc. | Modified physiologically active proteins and medicinal compositions containing the same |
US5985627A (en) | 1997-02-28 | 1999-11-16 | Carlsberg Laboratory | Modified carboxypeptidase |
JPH1156378A (ja) | 1997-06-11 | 1999-03-02 | Nippon Chem Res Kk | 変異型ヒト成長ホルモンとその用途 |
SI0996629T1 (sl) | 1997-06-25 | 2006-12-31 | Applied Research Systems | Analogi glikoproteinskega hormona povezanega z disulfidi, priprava in uporaba |
US7306931B2 (en) | 2000-05-16 | 2007-12-11 | Bolder Biotechnology, Inc. | Method for refolding proteins containing free cysteine residues |
ATE375363T1 (de) * | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
JPH1192499A (ja) | 1997-09-22 | 1999-04-06 | Sumitomo Pharmaceut Co Ltd | ヒト成長ホルモン変異体 |
US6136536A (en) | 1997-10-29 | 2000-10-24 | Genetics Institute, Inc. | Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins |
JP2002504527A (ja) | 1998-02-27 | 2002-02-12 | ノボ ノルディスク アクティーゼルスカブ | 部分的に組織化したミセル様凝集物を形成する25%を越えるヘリックス成分を有するglp−2誘導体 |
EP1056775B1 (fr) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derives de gpl-1 et de l'extendine au profil d'action etendu |
WO1999043705A1 (fr) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derives de glp-1 tronques a l'extremite n-terminale |
EP1062240B1 (fr) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Derives de glp-1 modifies a l'extremite n-terminale |
DE69916811T2 (de) | 1998-02-27 | 2005-04-14 | Novo Nordisk A/S | Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden |
US6656922B2 (en) | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
US6358705B1 (en) | 1998-07-16 | 2002-03-19 | Novo Nordisk A/S | Method of making proteins in transformed yeast cells |
WO2000034331A2 (fr) | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues du glp-1 |
WO2000069911A1 (fr) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Peptides insulinotropes a longue duree d'action |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
AU5805500A (en) | 1999-07-07 | 2001-01-30 | Maxygen Aps | A method for preparing modified polypeptides |
EP1076066A1 (fr) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides abaissant le taux de glucose sanguin |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
GB2355009A (en) | 1999-07-30 | 2001-04-11 | Univ Glasgow | Peptides conjugated to bile acids/salts |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
JP2003519664A (ja) | 2000-01-11 | 2003-06-24 | ノボ ノルディスク アクティーゼルスカブ | Glp−1誘導体の経上皮送達 |
RU2278123C2 (ru) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
AU2001259063A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
AU2002219021A1 (en) * | 2001-01-11 | 2002-07-24 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
US20060183197A1 (en) * | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
ES2331909T3 (es) | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | Factor viii estabilizado con enlaces disulfuro modificados geneticamente. |
DK1412384T3 (da) | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
US7186797B2 (en) | 2001-08-10 | 2007-03-06 | Epix Pharmaceuticals, Inc. | Polypeptide conjugates with extended circulating half-lives |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
JP2005518786A (ja) | 2001-11-12 | 2005-06-30 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | ヒトにおける成長ホルモン変異とその用途 |
JP2005525302A (ja) | 2001-11-20 | 2005-08-25 | ファルマシア・コーポレーション | 化学的に修飾されたヒト成長ホルモンコンジュゲート |
JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
FR2836382B1 (fr) | 2002-02-28 | 2004-08-13 | Biomerieux Sa | Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic |
WO2004065621A1 (fr) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques |
EP1496924A4 (fr) | 2002-04-10 | 2007-05-30 | Lilly Co Eli | Traitement de la gastroparesie |
SI1499719T1 (sl) | 2002-04-30 | 2011-03-31 | Bayer Healthcare Llc | Polipeptidne variante faktorja VII ali VIIa |
EP1539960B1 (fr) | 2002-09-09 | 2010-04-28 | Hanall Pharmaceutical Co., Ltd. | Polypeptides modifiés d'interferon alpha résistant aux protéases |
WO2004074315A2 (fr) | 2003-02-19 | 2004-09-02 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Analogues de glp-1 |
JP2007524584A (ja) | 2003-05-09 | 2007-08-30 | ノボ ノルディスク アクティーゼルスカブ | 肥満の治療に使用するペプチド |
WO2005014035A2 (fr) | 2003-08-08 | 2005-02-17 | Novo Nordisk Health Care Ag | Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique |
CN101380476A (zh) * | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
WO2005028516A2 (fr) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Nouvelles etiquettes d'affinite pour les proteines plasmiques |
RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
TW200526254A (en) * | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
WO2005034988A1 (fr) | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Molecules a action prolongee contenues dans des formulations a liberation prolongee |
JP2007537142A (ja) | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | アルブミン様物質に結合した新規のglp−1類似物 |
AU2004298424A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel GLP-1 compounds |
EP2368579A1 (fr) | 2004-01-21 | 2011-09-28 | Novo Nordisk Health Care AG | Conjugaison au moyen de transglutaminase de peptides |
US20070105770A1 (en) | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
JP2007519422A (ja) | 2004-02-02 | 2007-07-19 | アンブレツクス・インコーポレイテツド | 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用 |
SI1740213T1 (sl) | 2004-04-07 | 2012-04-30 | Ares Trading Sa | Tekoäśa formulacija rastnega hormona |
US7906137B2 (en) | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
ES2564167T3 (es) | 2004-07-08 | 2016-03-18 | Novo Nordisk A/S | Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol |
US20090176967A1 (en) | 2004-08-02 | 2009-07-09 | Novo Nordisk Healthcare A/G | Conjugation of FVII |
JP2008515856A (ja) | 2004-10-07 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 遅延性glp−1化合物 |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
AU2005322019B2 (en) | 2004-12-22 | 2010-08-26 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
EP1863537A2 (fr) | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Agonistes a base de peptide dimere contre le recepteur de glp-1 |
US8603972B2 (en) | 2005-03-18 | 2013-12-10 | Novo Nordisk A/S | Extended GLP-1 compounds |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
WO2006134148A2 (fr) | 2005-06-15 | 2006-12-21 | Novo Nordisk Health Care Ag | Conjugaison mediee par la transglutaminase d'une hormone de croissance |
EP2360170A3 (fr) | 2005-06-17 | 2012-03-28 | Novo Nordisk Health Care AG | Réduction et dérivatisation de protéines obtenues par génie génétique comprenant au moins une cystéine non native |
WO2007020291A1 (fr) | 2005-08-18 | 2007-02-22 | Novo Nordisk Health Care Ag | Amélioration de la spécificité des transglutaminases vis-à-vis d'un substrat |
KR20080038391A (ko) | 2005-08-30 | 2008-05-06 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 페그화 성장 호르몬의 액체 제제 |
CN1939534B (zh) | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
AU2007215566A1 (en) | 2006-01-19 | 2007-08-23 | Ambrx, Inc. | Non-natural amino acid polypeptides having modulated immunogenicity |
WO2007093594A1 (fr) | 2006-02-14 | 2007-08-23 | Novo Nordisk Health Care Ag | Couplage de polypeptides à l'extrémité c |
AU2007271150A1 (en) * | 2006-07-07 | 2008-01-10 | Novo Nordisk Health Care Ag | New protein conjugates and methods for their preparation |
ES2745411T3 (es) | 2006-07-27 | 2020-03-02 | Wang Nai Fang | Compuestos y composiciones de arilsulfanilo para administración de agentes activos |
JP2010500886A (ja) | 2006-08-18 | 2010-01-14 | ノボ ノルディスク ヘルス ケア アーゲー | 改善された特異性を有するトランスグルタミナーゼ変異体 |
US20080095837A1 (en) | 2006-08-31 | 2008-04-24 | Emisphere Technologies, Inc. | Human growth hormone formulations |
PT2059260E (pt) | 2006-08-31 | 2013-09-03 | Novartis Ag | Composições farmacêuticas compreendendo hgh para distribuição oral |
JP5390404B2 (ja) | 2007-02-16 | 2014-01-15 | エミスフェアー・テクノロジーズ・インク | 活性薬剤を送達するための環状部分を有する化合物及び組成物 |
GB0716328D0 (en) | 2007-08-21 | 2007-10-03 | Univ Bath | Detection and functionalisation of S-nitrosylated polypeptides |
US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
CN102112157B (zh) | 2008-08-06 | 2013-05-29 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内效能的缀合蛋白 |
CN102149726A (zh) | 2008-09-09 | 2011-08-10 | 诺沃—诺迪斯克保健股份有限公司 | 稳定性提高的生长激素共轭物 |
JP5591243B2 (ja) * | 2008-09-12 | 2014-09-17 | ノボ・ノルデイスク・エー/エス | ペプチド又はタンパク質のアシル化の方法 |
CN102292349B (zh) * | 2009-01-22 | 2016-04-13 | 诺沃—诺迪斯克保健股份有限公司 | 稳定的生长激素化合物 |
CN102333788A (zh) | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
TWI508737B (zh) * | 2010-01-22 | 2015-11-21 | 諾佛 儂迪克股份有限公司 | 具有延長的活體內功效的生長激素 |
US9211342B2 (en) | 2010-01-22 | 2015-12-15 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds resistant to proteolytic degradation |
EP2536434B1 (fr) | 2010-02-16 | 2016-04-20 | Novo Nordisk A/S | Procédé de purification |
WO2014166836A1 (fr) | 2013-04-05 | 2014-10-16 | Novo Nordisk A/S | Formulation de composés d'hormone de croissance |
-
2011
- 2011-01-24 TW TW100102456A patent/TWI508737B/zh active
- 2011-01-24 CN CN201610206249.7A patent/CN106139158B/zh active Active
- 2011-01-24 CN CN201180015252.6A patent/CN103002918B/zh active Active
- 2011-01-24 RS RSP20191198 patent/RS59459B1/sr unknown
- 2011-01-24 JP JP2012549377A patent/JP5875527B2/ja active Active
- 2011-01-24 SI SI201131785T patent/SI2525834T1/sl unknown
- 2011-01-24 PL PL11705470T patent/PL2525834T3/pl unknown
- 2011-01-24 EP EP11705470.0A patent/EP2525834B1/fr active Active
- 2011-01-24 CN CN201180006742.XA patent/CN102834109B/zh not_active Expired - Fee Related
- 2011-01-24 RU RU2012134975/10A patent/RU2605627C2/ru active
- 2011-01-24 KR KR1020127021413A patent/KR101813595B1/ko active IP Right Grant
- 2011-01-24 MX MX2012008000A patent/MX345736B/es active IP Right Grant
- 2011-01-24 AU AU2011208625A patent/AU2011208625C1/en active Active
- 2011-01-24 US US13/522,390 patent/US9695226B2/en active Active
- 2011-01-24 CA CA2787890A patent/CA2787890C/fr active Active
- 2011-01-24 BR BR112012018116-5A patent/BR112012018116B1/pt active IP Right Grant
- 2011-01-24 WO PCT/EP2011/050923 patent/WO2011089255A1/fr active Application Filing
-
2012
- 2012-06-24 IL IL220605A patent/IL220605A/en active IP Right Grant
-
2013
- 2013-12-18 US US14/132,919 patent/US8779109B2/en active Active
-
2015
- 2015-10-26 JP JP2015209720A patent/JP2016026204A/ja active Pending
-
2017
- 2017-05-04 US US15/586,960 patent/US20170239362A1/en not_active Abandoned
-
2019
- 2019-03-15 US US16/354,651 patent/US20190203213A1/en not_active Abandoned
- 2019-12-12 US US16/712,651 patent/US20200102568A1/en not_active Abandoned
-
2021
- 2021-05-21 FI FIC20210013C patent/FIC20210013I1/fi unknown
- 2021-05-26 NO NO2021023C patent/NO2021023I1/no unknown
- 2021-07-08 FR FR21C1029C patent/FR21C1029I2/fr active Active
- 2021-08-25 HU HUS2100029C patent/HUS2100029I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1029I2 (fr) | Hormones de croissance avec efficacité in vivo prolongée | |
BR112013011934A2 (pt) | configuração subframe | |
FI20106131A0 (fi) | Insertteri | |
SM201000007S1 (it) | Cinturino provvisto di due porzioni allargate recanti un ornamento | |
BR112013003568A2 (pt) | engate | |
BR112012019626A2 (pt) | estrutura de plantio e métodos. | |
EP2688412A4 (fr) | Agents insecticides et leurs utilisations | |
BR112012010510A2 (pt) | trator | |
EP2765853A4 (fr) | Améliorations apportées à des pièges pour animaux | |
FR2957220B1 (fr) | Tracteur enjambeur | |
EP2529618A4 (fr) | Leurre | |
NO20091963L (no) | Merdkonstruksjon | |
FR2943937B1 (fr) | Tondeuse corporelle aspirante | |
ZA201105609B (en) | Animal ectoparasite-controlling agent | |
ZA201105607B (en) | Animal ectoparasite-controlling agent | |
FR2956001B1 (fr) | Charrue semi-portee reversible hors-raie avec un moyen supplementaire de levage | |
ZA201105608B (en) | Animal ectoparasite-controlling agent | |
ZA201105606B (en) | Animal ectoparasite-controlling agent | |
GB2492266B (en) | Horseshoe with splaying feature and flexibility | |
EP2628374A4 (fr) | Tracteur | |
EP2628373A4 (fr) | Tracteur | |
FR2953365B1 (fr) | Tracteur enjambeur | |
GB201013276D0 (en) | Fishing game | |
ES1073234Y (es) | Celosia | |
FI20090392A (fi) | Uistin |